Nautilus Biotechnology, Inc.

As of June 11, 2025, Nautilus Biotechnology, Inc. is in a bearish trend with moderate strength, supported by bearish indicators across multiple time frames, including MACD, Bollinger Bands, and On-Balance Volume.

Nautilus Biotechnology, Inc. is a blank check company targeting business combinations in the healthcare sector, particularly in life sciences and medical technology. As of March 2025, it has a market cap of $88.38 million and reported a net profit loss of $17 million.

As of Jun 18, Nautilus Biotechnology, Inc. has a market capitalization of 88.38 million, with net sales of 0.00 million and a net profit of -68.66 million over the latest four quarters. The company reported shareholder's funds of 208.73 million and total assets of 242.74 million as of Dec 24.